Metabolic & Weight Research Peptides, Read Through Energy Balance

The short version

Desert Peptides is a reading desk, not a clinic and not a shop. It collects what the peer-reviewed literature says about three peptides studied for metabolic regulation and weight management: MOTS-c, retatrutide and semaglutide (Ozempic, Wegovy, Rybelsus).

All three touch the same simple arithmetic. Body weight moves when the energy taken in stops matching the energy spent. A peptide can lean on that balance in three places: it can lower how much food is eaten, raise how much energy is burned, or change how fuel is stored and handled inside cells.

Semaglutide leans on the first. It quiets appetite through the brain's feeding circuits, and the published mechanism describes it doing so without lowering energy expenditure. Retatrutide leans on the first and the second at once, because a glucagon-receptor arm sits alongside the appetite arms. MOTS-c — a peptide written into the mitochondrial genome rather than the cell nucleus — sits at the third, in how muscle takes up and burns glucose.

Sorting which peptide presses where, and how strong the evidence is behind each claim, is the whole job of this desk. Nothing here is medical advice, and no dose is recommended for any person.

The frame: intake, expenditure, storage

Weight-loss pharmacology is usually reported as a single number — percent body weight lost over a fixed window. That number hides the mechanism. Two compounds can land on the same figure by opposite routes, and the route is what determines the side-effect profile, the population studied and the questions that remain open.

Intake. The incretin arms — GLP-1 and GIP receptor agonism — are intake tools. They slow gastric emptying and act on hypothalamic and brainstem circuits that terminate a meal. In the STEP 1 trial, once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% at 68 weeks against -2.4% on placebo ^[16]. That result is a food-intake result.

Expenditure. Glucagon-receptor agonism is the expenditure lever, and retatrutide is the compound in this set that carries one. In the 48-week Phase 2 obesity trial, the 12 mg arm reached a mean -24.2% body-weight change against -2.1% on placebo ^[9]; a 2025 review characterises that step-change as the product of adding controlled glucagon activation, which raises energy expenditure and mobilises lipid, to the appetite arms ^[6]. A post-hoc metabolomic analysis of two Phase 2 trials found that changes in a fatty-acid-oxidation cluster mediated 23.2% of the weight-reduction response in participants without type 2 diabetes ^[12] — the clearest signal in this literature that substrate burning, not appetite alone, is doing part of the work.

Storage and cellular handling. MOTS-c operates below both levers. It raises AICAR and activates AMP-activated protein kinase, improving glucose handling in skeletal muscle, and it moves from the mitochondrion to the nucleus under metabolic stress to regulate nuclear gene expression ^[5]. A 2024 study identified casein kinase 2 as a direct binding target and tied tissue-specific modulation of it to muscle glucose uptake ^[1]. That is an efficiency story rather than a calorie-deficit story, and the human evidence for it is far thinner.

What a research peptide is — and what it is not

A peptide is a short chain of amino acids: the same chemistry as a protein, cut down to a length the body uses as a signal rather than as a structure. The compounds catalogued here are signalling peptides, either copied from a human hormone and re-engineered to last longer in circulation, or discovered inside the genome and studied as endogenous regulators.

"Research peptide" is a phrase that covers three very different regulatory situations, and this desk keeps them apart:

• Approved medicine. Semaglutide is FDA-approved across several indications and formulations, including type 2 diabetes, chronic weight management, cardiovascular risk reduction in established cardiovascular disease with overweight or obesity, and metabolic dysfunction-associated steatohepatitis. It is a prescription product, dispensed as a manufactured formulation.
• Investigational drug. Retatrutide is in Phase 3 and is not approved by any regulator. Every efficacy and safety figure on its page comes from a clinical trial publication, never from approved labelling, because no approved labelling exists.
• Research chemical. MOTS-c is not approved for human use anywhere, has completed no human efficacy trial, and is sold only for laboratory research. Anti-doping authorities treat it as a prohibited substance in elite sport.

Those three lines are not interchangeable, and the difference between them is usually a larger fact than any effect size reported alongside them.

What the trials actually measured

Endpoint discipline is the point of a briefing. A finding is only as wide as the population and the window it was measured in, so each entry on this desk records both.

The rows are deliberately unlike each other. A hard-outcome trial in 17,604 people and a biomarker association in 94 people are not the same class of evidence, and no amount of shared vocabulary makes them comparable. Where this desk reports a number it names the trial, the population and the duration; where a compound has no human trial at all, it says so rather than filling the gap with mechanism.

Doses appear on these pages only as a description of what a study administered. They are never a recommendation, and nothing here should be read as a protocol.